A significant number of patients with multiple myeloma continue to relapse and become refractory to currently available therapies, representing one of the largest and most challenging unmet needs in the disease, Ester in t Groen, EMEA Therapeutic Area head, Haematology, at Johnson & Johnson, stated in a news release.1 Making teclistamab monotherapy available to patients as early as second line, where it has the potential to meaningfully improve long-term outcomes and change the course of the disease, could bring new hope to patients and their families. To view or add a comment, sign in 7,151 followers
With the arrival of lower manufacturer prices and generic liraglutide, employers may find GLP-1 coverage more financially sustainable going forward
Fitness trackers can give you insights into your steps and active minutes, while progress photos can highlight shifts in body composition that numbers alone might miss
Potential Cartilage & Joint Repair Benefits Some researchers propose that AOD-9604 may aid in cartilage regeneration and joint recovery, potentially helping individuals with: Osteoarthritis or cartilage degradation Injury recovery, particularly in athletes Post-exercise inflammation reduction 4
Onze serie e-mails over leefstijl helpt je op weg
Why Quality Standards Matter When choosing any supplement, you are essentially trusting that brand with your biology